Strides Pharma to conduct trials in India for potential COVID-19 drug - (This is Money via NewsPoints Desk)

  • Strides Pharma Science received approval from the Drug Controller General of India to start clinical trials of the antiviral drug favipiravir to treat COVID-19, as reported in This is Money.

  • Favipiravir is manufactured under the brand name Avigan by a unit of Fujifilm and was approved for use as an anti-influenza drug in Japan in 2014.

  • Strides will do a bioequivalence study to compare the safety and efficacy of its drug with Avigan, a company spokesman said.

  • Strides' announcement comes after Glenmark Pharmaceuticals said last month it became the first drugmaker in India to get the nod to conduct favipiravir trials.

  • The Mumbai-based company has initiated late-stage clinical trials and expects study results by July or August.

To read more NewsPoints articles, click here.